Skip to main content
. 2019 Jan 11;10(4):536–550. doi: 10.18632/oncotarget.26570

Table 1. Microcolumn affinity tests.

Peptide Sequence [M+H]+calc. Supernatant [M+H]+ Last wash Elution
[M+H]+
CD160 (1–20) INITSSASQEGTRLNLIAbuTV-NH2 2101.36 2101.02 n.o. n.o.
CD160 (13–32) Ac-RLNLIAbuTVWHKKEEAEGFVV-NH2 2394.77 2394.37 n.o. 2394.32
CD160 (25–44) Ac-EEAEGFVVFLAbuKDRSGDAbuSP-NH2 2193.37 2193.21 n.o. 2193.19
CD160 (37–56) Ac-DRSGDAbuSPETSLKQLRLKRD-NH2 2327.56 2327.17 n.o. n.o.
CD160 (49–68) Ac-KQLRLKRDPGIDGVGEISSQ-NH2 2237.52 2237.10 n.o. n.o.
CD160 (61–80) Ac-GVGEISSQLMFTISQVTPLH-NH2 2185.50 2185.13 n.o. 2185.23
CD160 (73–92) Ac-ISQVTPLHSGTYQAbuAbuARSQK-NH2 2212.47 2210.11 n.o. 2210.19
CD160 (85–104) Ac-QAbuAbuARSQKSGIRLQGHFFSI-NH2 2271.58 2271.43 n.o. 2271.15
CD160 (97–116) Ac-LQGHFFSILFTETGNYTVTG-NH2 2273.50 - - -
*CD160(97-110) Ac-LQGHFFSILFTETG-NH2 1637.83 1637.65 n.o. 1637.65
*CD160(103-116) Ac-SILFTETGNYTVTG-NH2 1543.67 1565.60 [M+Na]+ n.o. n.o.
CD160(109-133) Ac-TGNYTVTGLKQRQHLEFSHNEGTLS-NH2 2859.07 2859.23 n.o. n.o.

n.o. – not observed; - – not results.